ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Association of Cytomegalovirus-Specific T Cell-Mediated Immunity with the Risk of CMV Infection Occurrence in Kidney Transplant Recipients.

D. Dęborska-Materkowska,1 A. Perkowska-Ptasińska,1 A. Sadowska,1 D. Sitarek,1 J. Gozdowska,1 M. Ciszek,2 M. Serwańska-Świętek,3 A. Jóźwik,3 P. Domagała,3 A. Kwiatkowski,3 M. Durlik.1

1Department of Transplantation Medicine, Nephrology and Internal Diseases, Warsaw Medical University, Warsaw, Poland
2Department of Immunology, Transplantology and Internal Diseases, Warsaw Medical University, Warsaw, Poland
3Department of General and Transplantation Surgery, Warsaw Medical University, Warsaw, Poland.

Meeting: 2016 American Transplant Congress

Abstract number: 309

Keywords: Cytomeglovirus, IgG, Kidney transplantation, T cells

Session Information

Session Name: Concurrent Session: CMV: Immune Monitoring & MicroRNA Responses

Session Type: Concurrent Session

Date: Monday, June 13, 2016

Session Time: 4:30pm-6:00pm

 Presentation Time: 5:30pm-5:42pm

Location: Room 306

Introduction

CMV remains the significant cause of morbidity in transplant recipients. Despite universal prophylaxis, late CMV infection occurs in high proportion of kidney transplant recipients. We aimed to evaluate if a specific viral T-cell response may allow for better identification of recipients at high risk of CMV infection after prophylaxis withdrawal.

Material and methods

We conducted prospective study to analyze the CMV-specific T-cell – mediated immunity in 86 kidney graft recipients subjected to antiviral prophylaxis. 18 CMV- D(+)/R(-),1 D(-)/(R(-) and 67 R(+) were examined within 1st and 3d months after transplantation. We used the Quantiferon-CMV (QF-CMV) assay to measure interferon-γ levels following in vitro stimulation with CMV antigens. Blood samples were monitored for CMV DNAemia using commercial QNAT calibrated to the WHO International Standard. Among 67 CMV R(+) the QF-CMV assay yielded reactive results in 51 (76%) (QF-CMV(+) and negative results in 16 (24%) individuals (QF-CMV(-). In CMV R(-) group 7 of 19 (37%) patients were found to be QF-CMV(+). In overall, 21 of 86 (19%) patients developed CMV viremia after prophylaxis withdrawal within next 12 post-transplant months, including 15 (22%) R(+) and 6 (32%) R(-). Among R(+), CMV infection occurred in 7 out of 16 (44%) recipients that were QF-CMV(-) and in 8 out of 51 (16%) of those QF-CMV(+). In a group of R(-), CMV infection evolved in 5 out of 12 (42%) of those QF-CMV (-), and in 1 out of 7 (14%) of recipients QF-CMV(+). Irrespective of initial CMV IgG status, CMV infection developed in 9 out of 58 (16%) of all QF-CMV(+) patients, and in 12 out of 28 (43%) recipients that were QF-CMV(-).

Conclusions:

The use of Quantiferon-CMV assay seems to be useful in CMV infection prediction after prophylaxis withdrawal. In the group of patients subjected to antiviral prophylaxis the negative result of QF-CMV better defines the risk of CMV infection occurrence than initial CMV IgG status.

CITATION INFORMATION: Dęborska-Materkowska D, Perkowska-Ptasińska A, Sadowska A, Sitarek D, Gozdowska J, Ciszek M, Serwańska-Świętek M, Jóźwik A, Domagała P, Kwiatkowski A, Durlik M. Association of Cytomegalovirus-Specific T Cell-Mediated Immunity with the Risk of CMV Infection Occurrence in Kidney Transplant Recipients. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Dęborska-Materkowska D, Perkowska-Ptasińska A, Sadowska A, Sitarek D, Gozdowska J, Ciszek M, Serwańska-Świętek M, Jóźwik A, Domagała P, Kwiatkowski A, Durlik M. Association of Cytomegalovirus-Specific T Cell-Mediated Immunity with the Risk of CMV Infection Occurrence in Kidney Transplant Recipients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/association-of-cytomegalovirus-specific-t-cell-mediated-immunity-with-the-risk-of-cmv-infection-occurrence-in-kidney-transplant-recipients/. Accessed June 5, 2025.

« Back to 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences